Pharmacist Considerations for New and Emerging Oral Oncolytics: Optimizing Therapy and Care for Patients Receiving Treatment

Pharmacist Considerations for New and Emerging Oral Oncolytics: Optimizing Therapy and Care for Patients Receiving Treatment

On-Demand 1.5-hour Accredited Webcast

Faculty Presenters
Ashley E. Glode, PharmD, BCOP
Assistant Professor
Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado

Kirollos S. Hanna, PharmD, BCPS, BCOP
Oncology Pharmacy Manager
M Health Fairview
Maple Grove, Minnesota

Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota
 
Program Description
The number of oral oncolytics approved by the Food and Drug Administration (FDA) has expanded in recent years, with continued growth expected. These therapies have the potential to impact patient care for both solid and hematologic malignancies. This activity will highlight novel oral oncolytics, with a specific focus on drug pharmacology and mechanism of action. Pharmacists are able to assist in treatment decisions for patients receiving oral oncolytics, and can also educate patients and caregivers on appropriate medication management. By determining the appropriate place in therapy for each oncolytic agent reviewed, pharmacists can assist in developing patient-specific treatment plans to optimize care for patients receiving oral oncolytics.

Target Audience: Specialty and oncology pharmacists
Type of Activity: Application
Release date: May 18, 2021
Expiration date: May 18, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Differentiate new and emerging oral oncolytics based on pharmacologic properties and mechanisms of action
• Determine the appropriate place in therapy for newly approved oral oncolytics based on patient- and disease-specific factors
• Use emerging clinical data of oral oncolytics to determine their potential place in treatment paradigms
• Customize pharmacist-led education for a patient beginning therapy with an oral oncolytic

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-216-H01-P. The activity is available for CE credit through May 18, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Kirollos S. Hanna, PharmD, BCPS, BCOP, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: Seagen, AbbVie
• Speakers Bureau: Seagen, AbbVie, Astellas, Rigel, Bristol Myers Squibb, BeiGene
• Stock/Shareholder: CVS

Ashley Glode, PharmD, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms